Hepatitis: Clinical Trials

80 trials for Hepatitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

80 unknown. 80 Phase 2, 15 Phase 1, 11 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 280Unknown 80
Phase 115Unknown 15
Phase 311Unknown 11

Follow Hepatitis: new trials by email Literature Review of Hepatitis trials Research Report on Hepatitis

Trials (filtered) newest first · largest first

All 80 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age
LR20062, DTaP-HepB-IPV-Hib vaccine - Diphtheria, Tetanus
Phase 2UnknownLG Chem3362024-10-022024-10-01
A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B
TQA3038 injection/placebo, Nucleotide drugs Control group - Hepatitis B, Chronic
Phase 1 / Phase 2UnknownChia Tai Tianqing Pharmaceutical Group Co., Ltd.1622024-06-012024-06-11
A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B
TQA3810 tablets+NUC, Placebo+NUC - Chronic Hepatitis B
Phase 2UnknownChia Tai Tianqing Pharmaceutical Group Co., Ltd.902024-03-202024-08-22
Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder
Glecaprevir/pibrentasvir, Placebo - PTSD
Phase 2 / Phase 3UnknownWhite River Junction Veterans Affairs Medical Center922023-12-182025-04-24
A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection
Ursodeoxycholic acid, Ropeginterferon alfa-2b, Tenofovir Alafenamide - Hepatitis D
Phase 2UnknownNational Taiwan University Hospital302023-02-242022-12-29
Safety Evaluation of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis
Fecal Microbiota Transplantation, Placebo - Alcoholic Hepatitis
Phase 1 / Phase 2UnknownPrasun Kumar Jalal502023-01-212025-01-23
A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patients With CHB
ZM-H1505R, ZM-H1505R placebo, Baraclude - Hepatitis B, Chronic
Phase 2UnknownShanghai Zhimeng Biopharma, Inc.902022-11-112023-05-08
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
N acetyl cysteine - Tuberculosis, Drug Induced Liver Injury
Phase 2 / Phase 3UnknownMahidol University822022-09-092023-02-22
Atorvastatin Use and Portal Hypertension in Patients With Hepatitis B Virus-related Liver Cirrhosis: A Randomized Controlled Trial
Atorvastatin 10mg, Placebo - Hepatitis B, Portal Hypertension
Phase 2UnknownSamsung Medical Center362022-08-012022-08-02
Antiviral Therapy for Patients With Chronic Hepatitis B Infection
Entecavir, Entecavir combined with Tenofovir Amibufenamide - Chronic Hepatitis B Virus Infection
Phase 2UnknownSun Yat-sen University2382022-05-102022-05-19
Liver Cancer Disparities in American Indian and Alaska Native Persons
Ultrasound or abbreviated MRI - Hepatocellular Carcinoma, Cirrhosis, Liver
Phase 2UnknownUniversity of Washington2002022-04-012024-06-04
Safety and Efficacy of Celecoxib Plus Nucleos(t)Ide Analogues on the Hepatitis B Surface Antigen of Virally Suppressed Subjects With Chronic Hepatitis B
Celecoxib, nucleos(t)ide analogue - To Evaluate the Safety and Efficacy of Celecoxib Plus Nucleos(t)Ide Analogues in Nucleos(t)Ide-treated Patients With Chronic Hepatitis B
Phase 2UnknownLai Wei472022-02-242022-08-03
ANRS HB07 IP-Cure-B Proof of Concept (PoC) Clinical Trial. Educating the Liver Immune Environment Through TLR8 Stimulation Followed by NUC Discontinuation
administration of SLGN in arm C, Discontinuation of NUC treatment in arms B and C - Hepatitis B, Chronic
Phase 2UnknownANRS, Emerging Infectious Diseases1002022-02-012022-03-14
A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)
Standard of care - Chronic Hepatitis B
Phase 2UnknownImmuneMed, Inc.322022-01-112023-06-15
Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis
Mycophenolate Mofetil, Solu-Medrol, Ursodeoxycholic acid - Hepatitis, Drug-Induced
Phase 2UnknownInge Marie Svane602021-04-072022-12-14
Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2
PurWet, FurFat, PurApo - Sequelae of; Infection, Post Infection Glomerulonephritis
Phase 1 / Phase 2UnknownAll Natural Medicine Clinic, LLC20002021-03-012021-05-26
Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH)
JKB-122, Placebo - Autoimmune Hepatitis
Phase 2UnknownTaiwanJ Pharmaceuticals Co., Ltd1202020-11-012020-09-01
A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B
APG-1387, Entecavir 0.5 mg - Hepatitis B, Chronic Hep B
Phase 2UnknownAscentage Pharma Group Inc.1222020-06-032021-08-26
"Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma
Cyclophosphamide, Multiple Signals loaded Dendritic Cells Vaccine - Hepatocellular Carcinoma
Phase 2UnknownYuehua Huang6002020-04-012020-10-29
Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients
Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody, Nucleoside/nucleotide analogues - Hepatitis B, Chronic
Phase 2UnknownHenlix, Inc442019-12-312020-10-20

Showing 20 of 80. Sign in to see all of them.

Narrower conditions

Hepatitis B, Chronic (22)  ·  Hepatitis C (22)  ·  Hepatitis C, Chronic (17)  ·  Hepatitis B (16)  ·  Liver Cirrhosis (5)  ·  Liver Diseases (5)  ·  Hepatitis, Chronic (4)  ·  Virus Diseases (4)  ·  Carcinoma, Hepatocellular (3)  ·  Depression (3)  ·  Hepatitis D (3)  ·  Hepatitis, Autoimmune (3)  ·  Infections (3)  ·  Stress Disorders, Post-Traumatic (3)

Broader conditions

Digestive System Diseases (80)  ·  Liver Diseases (75)  ·  Hepatitis, Viral, Human (69)  ·  Infections (69)  ·  Blood-Borne Infections (65)  ·  Communicable Diseases (65)  ·  Virus Diseases (65)  ·  Pathologic Processes (50)  ·  Pathological Conditions, Signs and Symptoms (50)  ·  Disease Attributes (46)  ·  Chronic Disease (45)  ·  Hepatitis, Chronic (42)  ·  RNA Virus Infections (38)  ·  DNA Virus Infections (35)

Interventions

entecavir (10)  ·  Ribavirin (8)  ·  peginterferon alfa-2a (6)  ·  Pharmaceutical Preparations (3)  ·  Rifaximin (3)  ·  Sofosbuvir (3)  ·  Tenofovir (3)  ·  Congresses as Topic (2)  ·  Ezetimibe (2)  ·  Hepatitis A Vaccines (2)  ·  Interleukin-7 (2)  ·  Metformin (2)  ·  Prednisone (2)  ·  Ursodeoxycholic Acid (2)  ·  adefovir dipivoxil (2)

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (3)  ·  Cytheris SA (3)  ·  Beijing 302 Hospital (2)  ·  Green Cross Corporation (2)  ·  LG Chem (2)  ·  National Taiwan University Hospital (2)  ·  Qilu Pharmaceutical Co., Ltd. (2)  ·  Santaris Pharma A/S (2)  ·  Third Affiliated Hospital, Sun Yat-Sen University (2)  ·  ANRS, Emerging Infectious Diseases (1)  ·  Aga Khan University (1)  ·  Ain Shams University (1)  ·  All Natural Medicine Clinic, LLC (1)  ·  Ascentage Pharma Group Inc. (1)  ·  Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1)

Countries

China (21)  ·  United States (14)  ·  France (6)  ·  South Korea (5)  ·  Italy (4)  ·  Spain (4)  ·  Taiwan (4)  ·  Austria (3)  ·  Brazil (3)  ·  Canada (3)  ·  Egypt (3)  ·  Puerto Rico (3)  ·  Australia (2)  ·  Germany (2)  ·  Poland (2)

Top investigators

Jinlin Hou, PhD (2)  ·  Junqi Niu, PhD (2)  ·  Alexander Thompson, MBBS (1)  ·  Amanda Quevedo, Sub Coord (1)  ·  Anastacio M Hoyumpa, Prof. M.D. (1)  ·  Anders G Vahlne, Professor (1)  ·  Bradley V Watts, MD, MPH (1)  ·  Bruno SF Souza, MD, Msc (1)  ·  Charles T Leach, Prof. M.D. (1)  ·  Cheng-Yuan Peng, MD, PhD (1)  ·  Chia-Yen Dai, MD, PhD (1)  ·  Christophe Hezode (1)  ·  Daiana V. Gomes, AssitSocial (1)

Results publications

PMID 15940636, PMID 15994231, PMID 16912304, PMID 17030856, PMID 17302367, PMID 18808318, PMID 19223649, PMID 19811343, PMID 20091678, PMID 2106474, PMID 22170794, PMID 2452123, PMID 24876849, PMID 25042797, PMID 25043197, PMID 26006200, PMID 28935432, PMID 30863450, PMID 3129521, PMID 33865507, PMID 34307188, PMID 35080256, PMID 37055910, PMID 37856013, PMID 41044745, PMID 41786454

NIH funding

2009 (2), P20CA252732 (1)